TITLE

A Double Blind, Randomized, Placebo-Controlled Phase II Study to Assess the Safety and Efficacy of Orally Administered SP-303 for the Symptomatic Treatment of Diarrhea in Patients With AIDS

AUTHOR(S)
Holodniy, Mark; Koch, Johannes; Mistal, Mark; Schmidt, Jamey Maimares; Khandwala, Atul; Pennington, James E.; Porter, Steven B.
PUB. DATE
November 1999
SOURCE
American Journal of Gastroenterology;Nov1999, Vol. 94 Issue 11, p3267
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: The aim of this study was to investigate the safety and effectiveness of orally administered SP-303 in patients with AIDS and diarrhea. METHODS: This is a multicenter, phase II, randomized, double blind, placebo-controlled study. HIV-positive subjects with a history of a CD4 count <200 or an AIDS-defining illness were admitted to an inpatient study unit and screened for diarrhea defined as at least three abnormal (i.e., soft or watery) stools and >200 g of abnormal stool weight over a 24-h period. Subjects discontinued all antidiarrheal agents >24 h before enrollment. Stool samples were studied for routine pathogens. Subjects received 500 mg p.o. of SP-303 or placebo every 6 h for 96 h (4 days). Stool frequency and weights were recorded. Subjects were monitored for symptoms and side effects and were seen 1 wk later in follow-up. RESULTS: A total of 26 subjects received SP-303, and 25 received placebo. There were no significant demographic differences between treatment arms. A total of 41 subjects (80%) were receiving antiretroviral therapy and 39 subjects (77%) were receiving at least one protease inhibitor. Stool studies revealed no pathogens in 48 of 51 patients (94%). There were no serious adverse events or laboratory abnormalities. The SP-303 treatment group demonstrated a mean reduction from baseline stool weight of 451 g/24 h versus 150 g/24 h with placebo on day 4 of treatment (p = 0.14), and a mean reduction in abnormal stool frequency of three abnormal stools in 24 h versus two in 24 h in the placebo group (p = 0.30). Daily measures analysis over 4 days of treatment demonstrated that SP-303 subjects had a significant reduction in stool weight (p = 0.008) and abnormal stool frequency (p = 0.04) when compared to placebo-treated subjects. CONCLUSIONS: SP-303 is safe and well tolerated. These results suggest that SP-303 may be effective in reducing stool weight and frequency in patients with AIDS and diarrhea.
ACCESSION #
17633261

 

Related Articles

  • Sunitinib rechallenge benefited select metastatic renal cell carcinomas.  // Hem/Onc Today;3/25/2010, Vol. 11 Issue 6, p36 

    The article discusses a study which examined the benefits of sunitinib for patients with metastatic renal cell carcinoma.

  • Four Antiretrovirals Reduced to Three After 48 Weeks.  // AIDS Treatment News;6/24/2005, Issue 413, p5 

    Presents a clinical trial of a 4-drug regimen to antiretroviral-naive patients. Assessment of patients after 48 weeks to either continue the regimen or drop the Sustiva; Discovery of the ability of the 3-drug regimen to maintain virologic control and immunological response; Detection of reduced...

  • Stool composition in factitial diarrhea: A 6-year experience with stool analysis. Phillips, Sidney; Donaldson, Leigh // Annals of Internal Medicine;7/15/95, Vol. 123 Issue 2, p97 

    Evaluates the utility of stool water analysis in the management of patients with chronic diarrhea. Role of chemical analysis of fresh stools in the identification of factitial diarrhea; Subdivision of chronic diarrheas; Limited role of fecal water analysis.

  • Tapeworm: A threat to human health and its preventive measures. Ahmad, Saood; Sajid, Sohail // Technology Times;2/1/2016, Vol. 7 Issue 5, p2 

    The article discusses kinds of worms like tapeworms, reasons of their spread to humans by eating beef, pig meat or raw fish meat; signs and symptoms of disease caused by tapeworms like nausea and diarrhea; and diagnosis of the disease by the examination of feces and preziquental drug for prevention.

  • Government Plans Wider AIDS Drug Trials. Helquist, Michael // Advocate;5/27/86, Issue 447, p20 

    Reports on the holding of expanded experimental drug trials in the U.S. in 1986 for people with AIDS and ARC. Estimated number of patients eligible for the trials.

  • Tolevamer, a Novel Nonantibiotic Polymer, Compared with Vancomycin in the Treatment of Mild to Moderately Severe Clostridium difficile-Associated Diarrhea. Louie, Thomas J.; Peppe, Jennifer; Watt, C. Kevin; Johnson, David; Mohammed, Rasheed; Dow, Gordon; Weiss, Karl; Simon, Stuart; John, Jr., Joseph F.; Garber, Gary; Chasan-Taber, Scott; Davidson, David M. // Clinical Infectious Diseases;8/15/2006, Vol. 43 Issue 4, p411 

    Background. Current antibiotic therapies for Clostridium difficile-associated diarrhea have limitations, including progression to severe disease, recurrent C. difficile-associated diarrhea, and selection for nosocomial pathogens. Tolevamer, a soluble, high-molecular weight, anionic polymer that...

  • MAGELLAN: Rivaroxaban efficacy comparable to enoxaparin in acutely ill.  // Cardiology Today;May2011, Vol. 14 Issue 5, p12 

    This article presents the results of the MAGELLAN trial which compared the efficacy of rivaroxaban and enoxaparin in acutely ill patients.

  • Resveratrol Has Potential as Chemotherapy, Study Finds. Breindl, Anette // BioWorld Today;3/20/2012, Vol. 23 Issue 44, p1 

    The article discusses research study on the clinical application of resveratrol. It references a study by Kyungjae Myung and colleagues, published in the March 19, 2012 online issue of "Proceedings of the National Academy of Sciences." The study described an assay designed to quickly screen...

  • Trubion presents positive data for anticancer compounds.  // PharmaWatch: Cancer;January 2004, Vol. 3 Issue 1, p14 

    Reports that Trubion Pharmaceuticals Inc.'s product candidates demonstrated effectiveness in depleting normal and malignant B-cells. B cells as mediators of immune-system dysregulation in autoimmune diseases; Trubion drugs' induction of apoptosis in malignant cells.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics